# Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

> **NCT00780403** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 220 (actual)

## Conditions studied

- Allergies

## Interventions

- **DRUG:** Desloratadine
- **DRUG:** Zyrtec® (cetirizine)

## Key facts

- **NCT ID:** NCT00780403
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780403, "Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00780403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*